Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Bioscns (NQ: APTO )

0.4200 +0.0099 (+2.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 187,017
Open 0.4100
Bid (Size) 0.4100 (30)
Ask (Size) 0.4300 (20)
Prev. Close 0.4101
Today's Range 0.4010 - 0.4350
52wk Range 0.3600 - 1.050
Shares Outstanding 93,653,662
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aptose Enters into $25 Million Committed Equity Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent #11653972 for "Medical Systems And Methods (For Resecting And... 
Via Benzinga

Performance

YTD
-30.00%
-30.00%
1 Month
-11.32%
-11.32%
3 Month
-31.87%
-31.87%
6 Month
-38.24%
-38.24%
1 Year
-55.94%
-55.94%

More News

Read More
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Analyst Expectations for Aptose Biosciences's Future
Via Benzinga
Canaccord Genuity Maintains Buy Rating for Aptose Biosciences: Here's What You Need To Know
Via Benzinga
Preview: Aptose Biosciences's Earnings
Via Benzinga
3 Stocks With 1,000% Upside Potential
Via InvestorPlace
Aptose Reports Results for the First Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2022
From Aptose Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 23, 2023
Via Benzinga
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
Via Benzinga
Aptose Biosciences Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.